Effect of a 2-week trial of functional electrical stimulation on gait function and quality of life in people with multiple sclerosis.

Int J MS Care

Hanger Prosthetics and Orthotic Clinic, Torrington, CT, USA (AD); Wethersfield, CT, USA (DVR); Woburn, MA, USA (AF); Somersworth, NH, USA (CA); Greenville, NC, USA (SM); Seattle, WA, USA (SS); Albany, NY, USA (TM); Columbia, SC, USA (KM); and New London, CT, USA (LP); and Innovative Neurotronics, Galveston, TX, USA (HR).

Published: October 2014

Background: Footdrop is a common gait deviation in people with multiple sclerosis (MS) leading to impaired gait and balance as well as decreased functional mobility. Functional electrical stimulation (FES) provides an alternative to the current standard of care for footdrop, an ankle-foot orthosis (AFO). FES stimulates the peroneal nerve and activates the dorsiflexor muscles, producing an active toe clearance and a more normal gait. This study was undertaken to determine the effects of a 2-week FES Home Assessment Program on gait speed, perceived walking ability, and quality of life (QOL) among people with MS-related footdrop.

Methods: Participants completed the Timed 25-Foot Walk test (T25FW) and two self-report measures: 12-item Multiple Sclerosis Walking Scale (MSWS-12) and 29-item Multiple Sclerosis Impact Scale (MSIS-29). Measures were taken without FES before and with FES after 2 weeks of full-time FES wear.

Results: A total of 19 participants (10 female, 9 male) completed the study; mean age and duration of disease were 51.77 ± 10.16 and 9.01 ± 7.90 years, respectively. Use of FES for 2 weeks resulted in a significant decrease in time to complete the T25FW (P < .0001), the MSWS-12 standardized score (P < .0001), and the MSIS-29 total (P < .0001), Physical subscale (P < .0001), and Psychological subscale (P = .0006) scores.

Conclusions: These results suggest that use of FES can significantly improve gait speed, decrease the impact of MS on walking ability, and improve QOL in people with MS-related footdrop even over a short period of time.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204375PMC
http://dx.doi.org/10.7224/1537-2073.2013-032DOI Listing

Publication Analysis

Top Keywords

multiple sclerosis
16
functional electrical
8
electrical stimulation
8
quality life
8
people multiple
8
fes
8
gait speed
8
walking ability
8
qol people
8
people ms-related
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.

The recent positive phase 3 clinical trials of new treatments and their licensing and roll-out in the US and other countries represents a major turning point in Alzheimer's disease research. As has been the case with many other diseases, e.g.

View Article and Find Full Text PDF

Background: The PANORAMA survey aimed to assess current treatment practice for individuals with new diagnoses of relapsing-remitting multiple sclerosis (RRMS) in the United Kingdom and to explore variations in treatment approaches with an emphasis on escalation vs early high-efficacy treatment (HET) and treatment goals.

Methods: Health care professionals (HCPs) from the UK treating patients with RRMS took part in interviews facilitated by a structured questionnaire. Data were analyzed descriptively using quantitative or qualitative methods, as appropriate.

View Article and Find Full Text PDF

Primary progressive multiple sclerosis (PPMS) affects 10-15% of multiple sclerosis patients and presents significant variability in the rate of disability progression. Identifying key biological features and patients at higher risk for fast progression is crucial to develop and optimize treatment strategies. Peripheral blood cell transcriptome has the potential to provide valuable information to predict patients' outcomes.

View Article and Find Full Text PDF

Neuromyelitis optica spectrum disorder (NMOSD) includes conditions with autoimmune genesis, which are manifested by attacks of optic neuritis (ON) and transverse myelitis (TM), and also express aquaporin 4 (NMO-IgG) or myelin oligo-endocytic glycoprotein (MOGAb) antibodies. In rare cases, the disease may also have a clinical presentation with only TM, without ON or with ON, without TM. These conditions are also included in the spectrum.

View Article and Find Full Text PDF

Factors associated with self-reported work ability among people with multiple sclerosis in Sweden.

Mult Scler J Exp Transl Clin

January 2025

Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Background: Work ability index (WAI) is an instrument that measures work ability in workplace surveys and health examinations in occupational health and research. It has been used in different population groups. But research is limited among people with multiple sclerosis (PwMS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!